Skip to main content

Mitigating Inflammation in asthma and pulmonary fibrosis using Berberine-loaded novel nanoparticles

Project Member(s): De Rubis, G., Paudel, K., Dua, K.

Funding or Partner Organisation: Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) (Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise)
Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) (Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise)

Start year: 2023

Summary: Asthma is a chronic inflammatory disease characterized by inflammation and reversible bronchoconstriction, which currently represents one of the world’s leading causes of mortality. Its symptoms occur in response to triggers such as infections (cold and flu), allergens (pollen, house dust mite [HDM], animal fur), smoke and others. Asthma is an incurable disease. Although effective treatments exist, these have severe side effects, and morbidity and mortality continue to increase. Pulmonary fibrosis is a rare, irreversible disease that manifests as remodelling, scarring, thickening and damaging of lungs, resulting in severe shortness of breath. Complications of lung fibrosis include pulmonary hypertension, respiratory failure, pneumothorax and lung cancer. This disease has life expectancy of less than five years and, currently, the only treatments available are aimed to improve symptoms and include oxygen therapy and pulmonary rehabilitation. Lung transplantation can occasionally be an option. Natural product-derived phytoconstituents such as berberine represent a prolific source of new therapeutic molecules, although issues including poor bioavailability and unsatisfactory pharmacokinetics hamper their use. Encapsulating and formulating these molecules within advanced drug delivery systems has the potential to overcome these limitations. To establish an advanced drug delivery system allowing direct lung administration through inhalation, our group developed nanoparticles (NP)-encapsulated berberine formulation (BBR-NPs) which showed strong in vitro anticancer, anti-inflammatory, and anti-oxidative activity. In particular, our group demonstrated that BBR-NPs attenuate cigarette smoke-induced oxidative stress, senescence and inflammation in 16HBE epithelial lung cells and RAW264.7 macrophages. This project builds on these previous research outputs, and is aimed at exploring the potential of BBR-NPs as a treatment strategy for asthma and pulmonary fibrosis.

Publications:

Bani Saeid, A, De Rubis, G, Williams, KA, Yeung, S, Chellappan, DK, Singh, SK, Gupta, G, Hansbro, PM, Shahbazi, M-A, Gulati, M, Kaur, IP, Santos, HA, Paudel, KR & Dua, K 2024, 'Revolutionizing lung health: Exploring the latest breakthroughs and future prospects of synbiotic nanostructures in lung diseases', Chemico-Biological Interactions, vol. 395, pp. 111009-111009.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Allam, VSRR, Malyla, V, Subramaniyan, V, Singh, SK, Panth, N, Gupta, G, Hansbro, PM, Chellappan, DK & Dua, K 2024, 'Involvement of osteopontin, EpCAM, estrogen receptor-alpha, and carbonic anhydrase IX protein in managing lung cancer via Berberine-loaded liquid crystalline nanoparticles', Pathology - Research and Practice, vol. 253, pp. 154971-154971.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Corrie, L, Mehndiratta, S, Patel, VK, Kumbhar, PS, Manjappa, AS, Disouza, J, Patravale, V, Gupta, G, Manandhar, B, Rajput, R, Robinson, AK, Reyes, R-J, Chakraborty, A, Chellappan, DK, Singh, SK, Oliver, BGG, Hansbro, PM & Dua, K 2024, 'Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 397, no. 5, pp. 2793-2833.
View/Download from: Publisher's site

Jessamine, V, Mehndiratta, S, De Rubis, G, Paudel, KR, Shetty, S, Suares, D, Chellappan, DK, Oliver, BG, Hansbro, PM & Dua, K 2024, 'The application of nanoparticles as advanced drug delivery systems in Attenuating COPD', Heliyon, vol. 10, no. 3, pp. e25393-e25393.
View/Download from: Publisher's site

Kokkinis, S, Singh, M, Paudel, KR, De Rubis, G, Bani Saeid, A, Jessamine, V, Datsyuk, J, Singh, SK, Vishwas, S, Adams, J, Hansbro, PM, Oliver, B, Gupta, G, Dureja, H & Dua, K 2024, 'Plant-based therapeutics for chronic obstructive pulmonary diseases: Nanoformulation strategies to overcome delivery challenges', Food Bioscience, vol. 58, pp. 103761-103761.
View/Download from: Publisher's site

Wong, SL, Gan, JS, De Rubis, G, Paudel, KR, Yeung, S, Chellappan, DK, Keng, PS & Dua, K 2024, 'Innovative phytoceutical-based drug delivery in the management of pulmonary fibrosis: A roadmap towards inhaled therapeutics', Journal of Drug Delivery Science and Technology, vol. 99, pp. 105942-105942.
View/Download from: Publisher's site

Bani Saeid, A, Patel, VK, Mehndiratta, S, Rajput, R, Kundu, RK, Singh, SK, Chellappan, DK, Kokkinis, S, De Rubis, G, Collet, T, Paudel, KR, Hansbro, PM & Dua, K 2023, 'Dissecting the in vitro fate of plant-derived bioactive encapsulated nanoparticles in lung diseases', Food Bioscience, vol. 56, pp. 103205-103205.
View/Download from: Publisher's site

Chakraborty, A, Paudel, KR, Wang, C, De Rubis, G, Chellappan, DK, Hansbro, PM, Samuel, CS & Dua, K 2023, 'Anti-inflammatory and anti-fibrotic effects of berberine-loaded liquid crystalline nanoparticles.', EXCLI J, vol. 22, pp. 1104-1108.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Liu, G, Agarwal, V, MacLoughlin, R, de Jesus Andreoli Pinto, T, Singh, SK, Adams, J, Nammi, S, Chellappan, DK, Oliver, BGG, Hansbro, PM & Dua, K 2023, 'Berberine-loaded engineered nanoparticles attenuate TGF-β-induced remodelling in human bronchial epithelial cells', Toxicology in Vitro, vol. 92, pp. 105660-105660.
View/Download from: Publisher's site

Malyla, V, De Rubis, G, Paudel, KR, Chellappan, DK, Hansbro, NG, Hansbro, PM & Dua, K 2023, 'Berberine nanostructures attenuate ß-catenin, a key component of epithelial mesenchymal transition in lung adenocarcinoma', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 396, no. 12, pp. 3595-3603.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Liu, G, Hansbro, P, Adams, J, Oliver, B & Dua, K 2023, 'Berberine-loaded nanoparticles attenuate TGF-β-induced remodelling features in human bronchial epithelial cells'.

Paudel, KR, Manandhar, B, Singh, SK, Gupta, G, Hansbro, PM, Chellappan, DK & Dua, K 2023, 'Cytotoxic mechanisms of berberine-phytantriol liquid crystalline nanoparticles against non-small-cell lung cancer.', IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, pp. 516-519.
View/Download from: Publisher's site

FOR Codes: Pharmacology and pharmaceutical sciences, Other biomedical and clinical sciences, Biochemistry and cell biology, Other biological sciences, Clinical health, Other health